Event

Please join us for the annual Mitchell J. Blutt, C'78, M'82, WG'87 Visiting Professorship in Entrepreneurism and Medicine lecture. 

This event highlights the crucial intersections between clinical medicine, research, industry, and health policy. 

Timeline

12:00 p.m. | Lunch Buffet Opens
12:30 p.m. | Program Begins
1:30 p.m. | Closing Remarks & Networking
2:00 p.m. | Event Concludes

Featured Speaker

Derrell D. Porter, M'97, WG'98, is a physician-entrepreneur with years of experience in the business of medicine, and one of the few experts with dual capabilities in developing and commercializing rapidly evolving cell therapies. Dr. Porter is currently CEO of an emerging biotech called cTRL Therapeutics, a company that harnesses circulating tumor reactive lymphocytes to broaden the power and reach of solid tumor cell therapy. Prior to his current role, he founded a cell therapy biotech called Cellevolve Bio. Dr. Porter has held roles of increasing responsibility at several leading biopharmaceutical companies: Atara Bio, Gilead, AbbVie, among others. He started his career at McKinsey & Company. Dr. Porter earned his MD from the University of Pennsylvania’s Perelman School of Medicine, where he was a Gamble Scholar, and his MBA from The Wharton School. He earned his Bachelor of Science in Neuroscience from the University of California, Los Angeles (UCLA). Additionally, he is on the boards of Passage Bio (NASDAQ: PASG), a Philadelphia-based genetics medicine company and Acumen Pharma (NASDAQ: ABOS), an Alzheimer's Disease company focused on developing amyloid beta oligomers targeted therapies. Dr. Porter also serves as a member of the Medical Advisory Council at the Perelman School of Medicine.

Register Here